87 related articles for article (PubMed ID: 23218563)
21. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Delcker A; Schoon ML; Oczkowski B; Gaertner HJ
Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
[TBL] [Abstract][Full Text] [Related]
22. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
Levine SZ; Leucht S
Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
[TBL] [Abstract][Full Text] [Related]
23. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
24. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
25. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
Psarros C; Theleritis CG; Paparrigopoulos TJ; Politis AM; Papadimitriou GN
Int J Geriatr Psychiatry; 2009 May; 24(5):518-22. PubMed ID: 19072747
[TBL] [Abstract][Full Text] [Related]
26. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
27. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia.
Levine SZ; Leucht S
Schizophr Res; 2012 Nov; 141(2-3):168-72. PubMed ID: 22995933
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
29. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia.
Levine SZ; Goldberg Y; Samara M; Davis JM; Leucht S
Schizophr Res; 2015 May; 164(1-3):122-6. PubMed ID: 25790904
[TBL] [Abstract][Full Text] [Related]
30. Atypical antipsychotic medications and the treatment of schizophrenia.
Lewis DA
Am J Psychiatry; 2002 Feb; 159(2):177-9. PubMed ID: 11823256
[No Abstract] [Full Text] [Related]
31. Comparative remission rates of schizophrenic patients using various remission criteria.
Beitinger R; Lin J; Kissling W; Leucht S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1643-51. PubMed ID: 18616969
[TBL] [Abstract][Full Text] [Related]
32. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
[TBL] [Abstract][Full Text] [Related]
34. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
[TBL] [Abstract][Full Text] [Related]
35. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.
Paillère-Martinot ML; Lecrubier Y; Martinot JL; Aubin F
Am J Psychiatry; 1995 Jan; 152(1):130-4. PubMed ID: 7802104
[TBL] [Abstract][Full Text] [Related]
36. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
37. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
38. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
Kang SG; Na KS; Lee HJ; Chee IS; Lee K; Lee J
J Clin Psychopharmacol; 2015 Apr; 35(2):158-62. PubMed ID: 25679126
[TBL] [Abstract][Full Text] [Related]
39. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
40. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.
Novick D; Haro JM; Suarez D; Vieta E; Naber D
Schizophr Res; 2009 Mar; 108(1-3):223-30. PubMed ID: 19070991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
